Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) considers adding lung scarring as an endpoint for its Phase 2b/3 COVID-19 study protocol

John Ballem  February 10, 2021

Lung Scarring Could be Another Endpoint for Algernon’s COVID-19 Study

Stockhouse Editorial February 10, 2021

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

GlobeNewswire February 10, 2021

Algernon Pharmaceuticals (CSE:AGN) signs agreement with Charles River Laboratories

Brieanna McCutcheon  February 8, 2021

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

GlobeNewswire February 8, 2021

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

GlobeNewswire February 3, 2021

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"

GlobeNewswire February 1, 2021

Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

GlobeNewswire January 22, 2021

Algernon Approved to Conduct Phase 3 Ifenprodil Study for COVID-19

Stockhouse Editorial January 20, 2021

Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants

GlobeNewswire January 19, 2021

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

GlobeNewswire January 19, 2021

Algernon Pharmaceuticals (CSE:AGN) highlights research review identifying potential COVID-19 treatment

Research January 11, 2021

New Research Suggests Ifenprodil as a Potential COVID-19 Treatment

Stockhouse Editorial January 11, 2021

Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment

GlobeNewswire January 11, 2021

Algernon Pharmaceuticals Lays out Roadmap for 2021

Stockhouse Editorial January 7, 2021

Algernon Pharmaceuticals Announces Plans for 2021

GlobeNewswire January 7, 2021

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

GlobeNewswire December 30, 2020

Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire December 24, 2020

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

GlobeNewswire December 23, 2020

Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast

GlobeNewswire December 21, 2020